Vasomedical EECP Heart Failure PMA Study Redirected Toward CMS Coverage
This article was originally published in The Gray Sheet
Executive Summary
Vasomedical will use cost data from its prospective evaluation of EECP in congestive heart failure (PEECH) trial to support a national Medicare coverage request for counterpulsation therapy
You may also be interested in...
Vasomedical Gains CHF Indication For Noninvasive Counterpulsation Therapy
A new congestive heart failure indication could create a 10-fold increase in the number of patients eligible for Vasomedical's EECP counterpulsation therapy system
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.